Stock NBIX NEUROCRINE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-08 pm EDT 		5-day change 1st Jan Change
139 USD -2.91% Intraday chart for Neurocrine Biosciences, Inc. -2.80% +5.51%
May. 08 Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults CI
May. 07 Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst? Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
PR
Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
CI
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
PR
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
PR
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst? Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
CI
Neurocrine Biosciences Presented CAHtalyst Pediatric Study Baseline Characteristics and CAHtalog Registry Data at PES 2024
AQ
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
PR
Neurocrine Biosciences Presents CAHtalyst Pediatric Study Baseline Characteristics and CAHtalog Registry Data at PES 2024
CI
UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating
MT
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $216 From $200, Maintains Outperform Rating
MT
Neurocrine Biosciences Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Jump Pre-Bell
MT
Transcript : Neurocrine Biosciences, Inc., Q1 2024 Earnings Call, May 01, 2024
Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Posts Q1 Revenue $515.3M, vs. Street Est of $512M
MT
Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Reports Q1 EPS $1.20, vs. Street Est of $1.29
MT
Neurocrine: Q1 Earnings Snapshot
AQ
Neurocrine Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Neurocrine Biosciences Reports First Quarter 2024 Financial Results
PR
Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024
CI
Neurocrine Gets FDA Approval for Ingrezza Sprinkle Capsules; Shares Rise After-Hours
MT
Neurocrine Biosciences' Huntington's disease drug gets FDA approval
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. News Neurocrine Biosciences, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW